Considering these findings, the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) was used to test if CRC cells that lack NCLX expression are more vulnerable to glycolysis inhibition. The gene discussed is SLC8B1; the disease is colorectal carcinoma.